Answers are grounded in this paper and cite their sources.
Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet.
No takes yet. Share an insight, caveat, or question.
Kataoka et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: